» Articles » PMID: 18985027

Finding Multiple Target Optimal Intervention in Disease-related Molecular Network

Overview
Journal Mol Syst Biol
Specialty Molecular Biology
Date 2008 Nov 6
PMID 18985027
Citations 71
Authors
Affiliations
Soon will be listed here.
Abstract

Drugs against multiple targets may overcome the many limitations of single targets and achieve a more effective and safer control of the disease. Numerous high-throughput experiments have been performed in this emerging field. However, systematic identification of multiple drug targets and their best intervention requires knowledge of the underlying disease network and calls for innovative computational methods that exploit the network structure and dynamics. Here, we develop a robust computational algorithm for finding multiple target optimal intervention (MTOI) solutions in a disease network. MTOI identifies potential drug targets and suggests optimal combinations of the target intervention that best restore the network to a normal state, which can be customer designed. We applied MTOI to an inflammation-related network. The well-known side effects of the traditional non-steriodal anti-inflammatory drugs and the recently recalled Vioxx were correctly accounted for in our network model. A number of promising MTOI solutions were found to be both effective and safer.

Citing Articles

Uses of Molecular Docking Simulations in Elucidating Synergistic, Additive, and/or Multi-Target (SAM) Effects of Herbal Medicines.

Rigby S Molecules. 2024; 29(22).

PMID: 39598795 PMC: 11597140. DOI: 10.3390/molecules29225406.


An adaptable ensemble model of the arachidonic acid cascade.

Uttley M, Horne G, Tsigkinopoulou A, Del Carratore F, Hawari A, Kiezel-Tsugunova M Mol Omics. 2024; 20(7):453-468.

PMID: 38860509 PMC: 11318654. DOI: 10.1039/d3mo00187c.


Identifying Qingkailing ingredients-dependent mesenchymal-epithelial transition factor-axiation "π" structuring module with angiogenesis and neurogenesis effects.

Kunming C, Jianan Y, Jun L, Shengpeng Z, Qixiang X, Yong X J Tradit Chin Med. 2024; 44(1):35-43.

PMID: 38213237 PMC: 10774727. DOI: 10.19852/j.cnki.jtcm.2024.01.004.


PINet 1.0: A pathway network-based evaluation of drug combinations for the management of specific diseases.

Hong Y, Chen D, Jin Y, Zu M, Zhang Y Front Mol Biosci. 2022; 9:971768.

PMID: 36330216 PMC: 9623281. DOI: 10.3389/fmolb.2022.971768.


Computational systems biology in disease modeling and control, review and perspectives.

Yue R, Dutta A NPJ Syst Biol Appl. 2022; 8(1):37.

PMID: 36192551 PMC: 9528884. DOI: 10.1038/s41540-022-00247-4.


References
1.
Shastry B . Genetic diversity and new therapeutic concepts. J Hum Genet. 2005; 50(7):321-328. DOI: 10.1007/s10038-005-0264-6. View

2.
Sams-Dodd F . Target-based drug discovery: is something wrong?. Drug Discov Today. 2005; 10(2):139-47. DOI: 10.1016/S1359-6446(04)03316-1. View

3.
Kusmak J . COX-2 inhibitors and the risk for cardiovascular events: a re-evaluation of the data and proposed mechanisms. S D J Med. 2006; 58(7):269-72. View

4.
Gupta E, Ito M . Lovastatin and extended-release niacin combination product: the first drug combination for the management of hyperlipidemia. Heart Dis. 2002; 4(2):124-37. DOI: 10.1097/00132580-200203000-00010. View

5.
Xiao H, Yang C . Combination regimen with statins and NSAIDs: a promising strategy for cancer chemoprevention. Int J Cancer. 2008; 123(5):983-90. DOI: 10.1002/ijc.23718. View